Histopathology of BRCA1- and BRCA2-associated breast cancer
- PMID: 16530420
- DOI: 10.1016/j.critrevonc.2006.01.006
Histopathology of BRCA1- and BRCA2-associated breast cancer
Abstract
Hereditary breast carcinomas that are attributable to BRCA1/2 mutations have their own morphological and immunohistochemical characteristics. BRCA1-associated carcinomas are poorly differentiated infiltrating ductal carcinomas that frequently show morphological features of typical or atypical medullary carcinoma. BRCA2-associated breast carcinomas tend to be of higher grade than sporadic age-matched controls. BRCA1tumors have been found to be more frequently estrogen receptor- and progesterone receptor-negative, and p53-positive than are age-matched controls, whereas these differences are not usually found in BRCA2-associated tumors. In addition, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER2 expression. Most BRCA1 breast carcinomas are characterized by the expression of basal (myoepithelial) markers, such as cytokeratin 5/6 and or P-cadherin. These features could be used to distinguish patients who are likely to carry a BRCA1 or BRCA2 germline mutation, thus indicating which gene should be screened for first in families with a high incidence of breast and ovarian cancer.
Similar articles
-
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14. Clin Cancer Res. 2003. PMID: 14506147
-
The molecular pathology of hereditary breast cancer.Pathobiology. 2008;75(2):85-94. doi: 10.1159/000123846. Epub 2008 Jun 10. Pathobiology. 2008. PMID: 18544963 Review.
-
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.Breast Cancer Res Treat. 2005 Mar;90(1):5-14. doi: 10.1007/s10549-004-1536-0. Breast Cancer Res Treat. 2005. PMID: 15770521
-
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.Breast Cancer Res Treat. 2006 Sep;99(1):85-90. doi: 10.1007/s10549-006-9184-1. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541313
-
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.Oncogene. 2006 Sep 25;25(43):5837-45. doi: 10.1038/sj.onc.1209875. Oncogene. 2006. PMID: 16998498 Review.
Cited by
-
Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers.NPJ Breast Cancer. 2024 Sep 14;10(1):81. doi: 10.1038/s41523-024-00691-x. NPJ Breast Cancer. 2024. PMID: 39277640 Free PMC article.
-
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.NPJ Breast Cancer. 2024 Jul 26;10(1):63. doi: 10.1038/s41523-024-00674-y. NPJ Breast Cancer. 2024. PMID: 39060255 Free PMC article.
-
BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.Cancers (Basel). 2020 May 15;12(5):1252. doi: 10.3390/cancers12051252. Cancers (Basel). 2020. PMID: 32429297 Free PMC article.
-
Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.BMC Cancer. 2018 Jun 8;18(1):647. doi: 10.1186/s12885-018-4537-9. BMC Cancer. 2018. PMID: 29884136 Free PMC article.
-
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z. Curr Treat Options Cardiovasc Med. 2018. PMID: 29497862 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
